Related Experiment Video
Updated: Apr 16, 2026

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
Published on: October 21, 2017
[The clinical and hemostasiological features of chronic hepatitides of different genesis]
Insights
Chronic mixed hepatitis (CMH) presents a more severe clinical course than chronic alcoholic hepatitis (CAH). Hemostasis parameters vary with disease stage, not significantly by hepatitis etiology.
Area of Science:
- Hepatology
- Biochemistry
- Hematology
Context:
- Chronic alcoholic hepatitis (CAH) and chronic mixed hepatitis (CMH), a combination of CAH and chronic hepatitis C, represent significant liver pathologies.
- Understanding the distinct clinical, biochemical, and hemostasiological profiles of these conditions is crucial for effective patient management.
Purpose:
- To conduct a comparative analysis of clinical, biochemical, and hemostasiological parameters in patients diagnosed with CAH versus CMH.
- To elucidate differences in disease severity and biochemical markers between these two forms of chronic hepatitis.
Summary:
- Sixty-three patients with chronic hepatitis were evaluated. CMH patients exhibited more pronounced clinical symptoms. Aspartate aminotransferase levels were lower in CAH, while gamma-glutamyl transpeptidase activity was higher. Both groups showed elevated von Willebrand factor and reduced platelet/erythrocyte aggregation compared to healthy individuals, with variations across disease stages.
Impact:
- CMH demonstrates a more severe disease progression compared to CAH.
- The hemostatic system's variability is linked to the disease stage rather than the specific etiology of hepatitis.
- Findings contribute to a better understanding of hepatitis pathophysiology and inform clinical decision-making.
Aim:
To comparatively characterize clinical, biochemical, and hemostasiological parameters in patients with chronic alcoholic hepatitis (CAH) and chronic mixed hepatitis (CMH), i.e. CAH + chronic hepatitis C.
Subjects And Methods:
Sixty-three patients (mean age 39.05±4.95 years) with chronic hepatitides of different etiology, who underwent general clinical, biochemical, and hemostasiological studies, were examined.
Results:
The frequency and duration of major clinical symptoms were maximally pronounced in the patients with CMH. Aspartate aminotransferase concentrations were significantly decreased only in the patients with CAH, remaining at higher levels in CMH. The activity of γ-glutamyl transpeptidase was twice higher in CAH. In the patients of both groups, the total concentration of nitrates and nitrites was recorded within the normal range and the activity of von Willebrand factor was significantly higher than normal. The aggregation of platelets and erythrocytes in the patients of all the groups was significantly lower than that in the healthy individuals, but differed at different disease stages.
Conclusion:
CMH was ascertained to have a more severe course. The hemostatic system did not significantly depend on the etiology of hepatitis, but was variable in different periods of various hepatitides.
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Liver Histology
Hepatocytes perform a variety of essential functions. They secrete...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

